TL;DR
Researchers have developed a novel system using noncanonical amino acids (ncAAs) to control the lifecycle of bacteriophage lambda (λ), enabling precise regulation of protein delivery from engineered bacteria. This approach offers two distinct modes for protein release and allows for independent control of multiple therapeutic proteins, paving the way for advanced combination therapies.
What Problem Does This Paper Address?
Genetically engineered bacteria hold immense promise as drug delivery systems, particularly for targeted therapies like cancer treatment. However, a significant challenge lies in precisely controlling the expression and release of therapeutic proteins, especially when multiple drugs are involved. Current methods often rely on a single inducer, limiting independent regulation and potentially leading to drug resistance or reduced efficacy. The need for new strategies that allow for specific, independent, and tunable control of protein drugs within these bacterial delivery systems is critical for advancing combination therapies.
Methods
The core innovation in this paper is the use of noncanonical amino acids (ncAAs) as molecular inducers to control the life cycle of bacteriophage lambda (λ) within engineered E. coli bacteria. This strategy leverages genetic code expansion, a technique that allows for the site-specific incorporation of ncAAs into proteins by using an orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA pair and a synthetic codon (typically an amber stop codon, TAG).
The researchers engineered a λ lysogen (a bacterium harboring the λ phage genome integrated into its own) to express a modified Cro protein. The Cro protein is a key regulator of the λ phage life cycle, controlling the switch between lysogeny (dormancy) and lysis (replication and cell bursting). By introducing a TAG stop codon into the cro gene, the researchers created a system where a functional Cro protein is only produced when a specific ncAA is present to be incorporated at the TAG site.
Two primary modes of delivery were developed:
- Mode 1 (Protein Release): The therapeutic protein of interest (POI) is expressed within the bacterial cell. Upon addition of the specific ncAA inducer, the Cro-ncAA variant is produced, triggering λ phage induction, bacterial lysis, and the release of the POI.
- Mode 2 (Sustained Protein Expression): The POI gene is integrated into the λ phage genome. When the phage is induced by the ncAA, released phage particles infect recipient E. coli cells, delivering the POI gene and leading to sustained expression of the therapeutic protein.
The study also focused on identifying suitable orthogonal aaRS/tRNA pairs and ncAAs, and screening for permissive sites within the Cro protein for ncAA incorporation. They demonstrated the mutual orthogonality of different ncAA-inducer pairs, allowing for the independent regulation of multiple proteins by using different ncAAs.
Datasets
Not discussed in the paper. The study relies on in vitro experiments with engineered bacterial strains and in vivo studies in mice.
Key Insights and Ideas
- ncAAs as precise prophage inducers: The most significant insight is the successful demonstration that specific ncAAs can act as highly precise molecular switches to trigger prophage induction and subsequent bacterial lysis. This bypasses the need for less controllable inducers like UV light or mitomycin C, which are unsuitable for in vivo applications.
- Dual-mode delivery system: The development of two distinct delivery modes (one-shot release vs. sustained expression) offers remarkable flexibility for tailoring therapeutic strategies to different needs.
- Orthogonal control for combination therapy: The ability to use different ncAAs to independently regulate multiple proteins is a major breakthrough for combination therapy. This allows for precise dosing and timing of different therapeutic agents delivered by the same bacterial platform.
- Minimal genetic engineering: The strategy requires relatively minimal genetic modifications, primarily the introduction of an orthogonal aaRS/tRNA pair and a TAG codon in the target gene, making it adaptable to various bacterial and phage systems.
- Safety of ncAAs: The study provides evidence for the in vivo safety of the ncAA Alock in mice, a crucial step towards clinical translation.
Key Results
- Efficient ncAA incorporation: The researchers identified and optimized the use of specific aaRS/tRNA pairs (e.g., MbPyIRS-349F/tRNAPyl) and ncAAs (e.g., Alock) for efficient incorporation into the Cro protein.
- Functional Cro-ncAA variants: They successfully engineered functional Cro variants (e.g., Cro-K8Alock) that, upon ncAA supplementation, triggered λ prophage induction and bacterial lysis.
- Mode 1 demonstrated: Alock induction led to the release of intracellular proteins, including a reporter protein (mNeonGreen), from lysed bacteria.
- Mode 2 demonstrated: Phage particles carrying a reporter gene, when delivered to recipient E. coli, resulted in sustained protein expression.
- In vivo efficacy: The system demonstrated prophage induction and protein release in the murine gut environment, suggesting its potential for in vivo therapeutic applications.
- Independent regulation: Using two orthogonal ncAA pairs (Alock and pIF), the researchers achieved independent induction of mNG and mCherry expression in a mixed population of engineered bacteria.
Limitations and Future Work
- ncAA incorporation efficiency: While efficient, the incorporation of ncAAs into the Cro protein was noted to be less effective than wild-type Cro in some instances, potentially impacting the overall efficacy of prophage induction. The authors suggest exploring strategies to improve ncAA incorporation, such as knocking out translation termination release factors or using orthogonal ribosomes.
- Oral delivery challenges: The acidic gastric environment was identified as a potential barrier for oral delivery of the bacterial system, suggesting the need for protective materials to ensure effective release in the intestinal environment.
- Host specificity: While the study focused on E. coli and λ phage, the authors propose that similar strategies could be applied to other phage-bacteria systems, but this would require careful consideration of host specificity and potential toxicity.
- Optimization for specific applications: Further optimization of promoter strength and ncAA selection may be necessary for specific therapeutic applications and to fine-tune drug dosages.
- Broader ncAA and phage applications: The authors envision expanding the use of ncAAs to regulate other phage proteins and to engineer different prophage-bacteria systems for disease-specific therapies. They also suggest using this technology to study phage biology and phage-bacteria interactions.
Summary updated